United StatesÚltimas notícias

Vor Bio (NASDAQ:VOR) has secured a $75 million private placement with TCGX, a transaction executed on March 27, 2026, that significantly bolsters the company's balance sheet.

Eikon Therapeutics (NASDAQ:EIKN), a clinical-stage biotechnology company focused on developing novel medicines through advanced imaging and machine learning platforms, reported corporate and clinical updates on March 30, 2026, alongside its full-year 2025 financial results.

Functional Brands (NASDAQ:MEHA), a leading developer and manufacturer of functional health and wellness products, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

Rezolve Ai (NASDAQ:RZLV), a global leader in AI-powered conversational commerce and retail engagement, today announced its financial results for the full year ended December 31, 2025.

Uber Technologies (NYSE:UBER) today announced a definitive agreement to acquire Blacklane, a premier global chauffeur service, marking a significant escalation in Uber’s strategy to dominate the high-margin luxury and corporate travel segments

Soluna Holdings (NASDAQ:SLNH), a specialized developer of green data centers for intensive computing applications such as Bitcoin mining and artificial intelligence, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

Terrestrial Energy (NASDAQ:IMSR), a developer of Generation IV advanced nuclear technology, today announced its financial results and program milestones for the fourth quarter and full year ended December 31, 2025.

Veradermics (NYSE:MANE), a late-clinical stage biopharmaceutical firm specializing in aesthetic and dermatological therapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

USA Rare Earth (NASDAQ:USAR) reported a transformative shift in its financial position and operational footprint for the full year 2025, underpinned by a massive capital injection that establishes the company as a primary contender in the race to build a non-Chinese permanent magnet supply chain.

Connect Biopharma Holdings (NASDAQ:CNTB), a clinical-stage biopharmaceutical company focused on chronic inflammatory diseases, today reported positive topline preliminary results from its Phase 1 clinical pharmacology study (CBP-201-105) evaluating an intravenous (IV) formulation of rademikibart.

Boardwalk Pipelines (NYSE:SR) announced today that it has entered into a definitive agreement to acquire Spire Marketing from Spire.

United Therapeutics (NASDAQ:UTHR), a public benefit corporation, today announced that its pivotal TETON-1 study evaluating nebulized Tyvaso® (treprostinil) for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint.